An updated meta-analysis on the efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor treatment of anemia in nondialysis-dependent chronic kidney disease

BACKGROUND: Renal anemia, a common complication and threat factor of chronic kidney disease (CKD), has long been treated with injectable erythropoietin-stimulating agents (ESAs). As concerns regarding cardiovascular safety and erythropoietin resistance to ESAs have emerged, alternative therapies are...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Hanxue, Li, Peiyun, Zhang, Hong-Liang, Jia, Linpei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
State-of-the-Art Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512776/
https://www.ncbi.nlm.nih.gov/pubmed/37724564
http://dx.doi.org/10.1080/0886022X.2023.2258986

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512776/
https://www.ncbi.nlm.nih.gov/pubmed/37724564
http://dx.doi.org/10.1080/0886022X.2023.2258986

Ejemplares similares